RNAC Valuation

Cartesian Therapeutics Inc

Add to Watchlist

Advanced Chart

12.180

+0.13(1.079%)1D

Overview
Forecast
Valuation
Earnings

RNAC Relative Valuation

RNAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNAC is overvalued; if below, it's undervalued.

Historical Valuation

Cartesian Therapeutics Inc (RNAC) is now in the Fair zone, suggesting that its current forward PS ratio of 98.86 is considered Fairly compared with the five-year average of -6.36. The fair price of Cartesian Therapeutics Inc (RNAC) is between 1.93 to 12.67 according to relative valuation methord.

Relative Value

Fair Zone

1.93-12.67

Current Price：12.29

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-14.34

P/B

Median3y

117.21

Median5y

117.21

-13.16

FCF Yield

Median3y

-18.85

Median5y

-18.85

Competitors Valuation Multiple

The average P/S ratio for RNAC's competitors is 18.14, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC) exhibits a P/S ratio of 98.86, which is 445.04% above the industry average. Given its robust revenue growth of -81.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RNAC.O

Cartesian Therapeutics Inc

98.86

Average P/S: 18.14

-81.16%